RxDoctor Payments Data

Tianshu Zhang, MD

Neurology · Metuchen, NJNPI 1790851541

Payments from drug & device makers

$1,699in general payments, 2019–2025

Across 65 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$520
  • AbbVie$480
  • Eisai Inc.$401
  • SK Life Science, Inc.$76
  • Pfizer$46
  • Bristol Myers Squibb$44
  • plus $131 from 8 others

What the payments were for

  • Food & beverage$1,67298%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,699 in reported general payments places this provider in the 45th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$259,520
Medicare patients
460
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Zolmitriptan19$18,879
Levetiracetam273$7,393
Memantine Hcl ErMemantine Hcl40$2,634
Carbidopa-LevodopaCarbidopa/Levodopa95$2,102
Memantine Hcl141$2,009
Divalproex Sodium ErDivalproex Sodium37$1,890
Oxcarbazepine32$1,813
Divalproex Sodium26$1,807
Gabapentin197$1,719
Lacosamide57$1,544
Levetiracetam ErLevetiracetam19$1,370
Phenytoin Sodium Extended72$1,273
Carbidopa-Levodopa ErCarbidopa/Levodopa18$1,161
Valproic AcidValproic Acid (As Sodium Salt)14$879
Primidone52$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerDilantin$46$21512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 521 neurology providers in New Jersey.

Other neurology in Metuchen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →